Treatment and prognosis;Tratamiento y pronóstico

Reumatologia Clinica

Volumn 5, Issue SUPPL. 3, 2009, Pages 35-39

  Catoggio, Luís J ^a,b   Soriano, Enrique R ^a,b   Rosa, Javier E ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b School of Medicine   (Argentina)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory myopathies; Myositis

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; ISONIAZID; MEPREDNISONE; METHOTREXATE; MUSCLE ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CALCINOSIS; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; HUMAN; INCLUSION BODY MYOSITIS; IRRADIATION; LIVER TOXICITY; MUSCLE BIOPSY; MUSCLE STRENGTH; MYOSITIS; NUCLEAR MAGNETIC RESONANCE; PANCREATITIS; PHOTOSENSITIVITY; PLASMAPHERESIS; POLYMYOSITIS; PROGNOSIS; SIDE EFFECT; TREATMENT RESPONSE; DIAGNOSTIC PROCEDURE; DRUG EFFICACY;

EID: 71849101212     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2009.07.004     Document Type: Article

References (30)

1. Bunch T.W., Worthington J.W., Combs J.J., Ilstrup D.M., and Engel A.G. Azathioprine with prednisone for polymyositis. Ann Intern Med 92 (1980) 365-369
2. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 30 (1993) 1993-2000
3. Danko K., Ponyi A., Constantin T., Borgulya G., and Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: A longitudinal study of 162 cases. Medicine (Baltimore) 83 (2004) 35-42
4. Maugars Y.M., Berthelot J.M., Abbas A.A., Mussini J.M., Nguyen J.M., and Prost A.M. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 14 (1996) 263-274
5. Plotz P.H., Rider L.G., Targoff I.N., Raben N., O'Hanlon T.P., and Miller F.W. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 122 (1995) 715-724
6. Winkelmann R.K., Mulder D.W., Lambert E.H., Howard Jr. F.M., and Diessner J.R. Course of dermatomyositis polymyositis: Comparison of untreated and cortisone-treated patients. Mayo Clin Proc 43 (1968) 545-556
7. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971-82.
8. Oddis C.V. Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 12 (2000) 492-497
9. Homik J.E., Craney A., Shea B., Tugwell P., Wells G., Adachi J.D., et al. A metanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 26 (1999) 1148-1157
10. Newman E.D., and Scott D.W. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol 1 (1995) 99-102
11. Zieglschmid Adams M.E., Pandya A.G., Cohen S.B., and Sontheimer R.D. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 32 (1995) 754-757
12. Imamura P.M., Catoggio L.J., Soriano E.R., Baruzzo C., and Mayorga L.M. Características clínico-serológicas de 34 pacientes argentinos con dermato-polimiositis. Rev Argentina Reumatol 4 (1993) 90-98
13. Spalton D.J., Verdon Roe D.M., and Hughes G.R.V. Hydroxychloroquine, dosage parameters and retinopathy. Lupus 2 (1993) 355-358
14. Brulhart L., Waldburger J.M., and Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 65 (2006) 974-975
15. Noss E.H., Hausner-Sypeck D.L., and Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33 (2006) 1021-1026
16. Qushmaq K.A., Chalmers A., and Esdaile J.M. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: Population based experience in 6 patients and literature review. J Rheumatol 27 (2000) 2855-2859
17. Oddis C.V., Sciurba F.C., Elmagd K.A., and Starzl T.E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353 (1999) 1762-1763
18. Pisoni C.N., Cuadrado M.J., Khamashta M.A., Hughes G.R., and D'Cruz D.P. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 46 (2007) 516-518
19. Villalba L., Hicks J.E., Adams E.M., Sherman J.B., Gourley M.F., Leff R.L., et al. Treatment of refractory myositis. Arthritis Rheum 41 (1998) 392-399
20. Hengstman G.J., Van den Hoogen F.H., Barrera P., Netea M.G., Pieterse A., Van de Putte L.B., et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: Preliminary observations. Eur Neurol 50 (2003) 10-15
21. Park J.H., Vital T.L., Ryder N.M., Hernanz-Schulman M., Partain C.L., Price R.R., et al. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 37 (1994) 736-746
22. Kagen L.J., Hochman R.B., and Stron E.W. Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatomyositis): Report of three cases and review of the literature. Arthritis Rheum 28 (1985) 630-636
23. Yoshida T., Koga H., Saitoh F., Sakamoto M., Harada M., Yoshida H., et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 38 (1999) 733-738
24. Wortmann R.L. The dilemma of treating patients with inclusion body myositis. J Rheumatol 19 (1992) 1327-1329
25. Dalakas M.C., Koffman B., Fujii M., Spector S., Sivakumar K., and Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56 (2001) 323-327
26. Dalakas M.C., Sonies B., Dambrosia J., Sekul E., Cupler E., and Sivakumar K. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 48 (1997) 712-716
27. Walter M.C., Lochmuller H., Toepfer M., Schlotter B., Reilich P., Schroder M., et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 247 (2000) 22-28
28. Soueidan S.A., and Dalakas M.C. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43 (1993) 876-879
29. Amato A.A., Barohn R.J., Jackson C.E., Pappert E.J., Sahenk Z., and Kissel J.T. Inclusion body myositis: Treatment with intravenous immunoglobulin. Neurology 44 (1994) 1516-1518
30. Cherin P., Pelletier S., Teixeira A., Laforet P., Simon A., Herson S., et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58 (2002) 326-327